JP7305624B2 - 新規抗ＣＤ３ε抗体 - Google Patents

新規抗ＣＤ３ε抗体 Download PDF

Info

Publication number
JP7305624B2
JP7305624B2 JP2020516462A JP2020516462A JP7305624B2 JP 7305624 B2 JP7305624 B2 JP 7305624B2 JP 2020516462 A JP2020516462 A JP 2020516462A JP 2020516462 A JP2020516462 A JP 2020516462A JP 7305624 B2 JP7305624 B2 JP 7305624B2
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
cd3ε
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534830A (ja
JP2020534830A5 (https=
Inventor
リ，ジン
メイ，キン
Original Assignee
ウーシー バイオロジクス アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウーシー バイオロジクス アイルランド リミテッド filed Critical ウーシー バイオロジクス アイルランド リミテッド
Publication of JP2020534830A publication Critical patent/JP2020534830A/ja
Publication of JP2020534830A5 publication Critical patent/JP2020534830A5/ja
Priority to JP2023105809A priority Critical patent/JP7737193B2/ja
Application granted granted Critical
Publication of JP7305624B2 publication Critical patent/JP7305624B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020516462A 2017-09-21 2018-09-20 新規抗ＣＤ３ε抗体 Active JP7305624B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023105809A JP7737193B2 (ja) 2017-09-21 2023-06-28 新規抗ＣＤ３ε抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/102622 2017-09-21
CN2017102622 2017-09-21
PCT/CN2018/106618 WO2019057099A1 (en) 2017-09-21 2018-09-20 NOVEL ANTI-CD3EPSILON ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023105809A Division JP7737193B2 (ja) 2017-09-21 2023-06-28 新規抗ＣＤ３ε抗体

Publications (3)

Publication Number Publication Date
JP2020534830A JP2020534830A (ja) 2020-12-03
JP2020534830A5 JP2020534830A5 (https=) 2021-10-28
JP7305624B2 true JP7305624B2 (ja) 2023-07-10

Family

ID=65811028

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020516462A Active JP7305624B2 (ja) 2017-09-21 2018-09-20 新規抗ＣＤ３ε抗体
JP2023105809A Active JP7737193B2 (ja) 2017-09-21 2023-06-28 新規抗ＣＤ３ε抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023105809A Active JP7737193B2 (ja) 2017-09-21 2023-06-28 新規抗ＣＤ３ε抗体

Country Status (18)

Country Link
US (3) US11440962B2 (https=)
EP (1) EP3684806A4 (https=)
JP (2) JP7305624B2 (https=)
KR (2) KR20250046337A (https=)
CN (2) CN115991777A (https=)
AU (2) AU2018336519B2 (https=)
BR (1) BR112020004992A2 (https=)
CA (1) CA3074130A1 (https=)
EA (1) EA202090800A1 (https=)
IL (2) IL273393B1 (https=)
MX (1) MX2020003087A (https=)
MY (1) MY199530A (https=)
PH (1) PH12020550078A1 (https=)
SA (2) SA520411577B1 (https=)
SG (1) SG11202001358RA (https=)
TW (2) TWI820041B (https=)
WO (1) WO2019057099A1 (https=)
ZA (1) ZA202001314B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102820804B1 (ko) 2017-09-22 2025-06-16 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
AU2018334886B2 (en) 2017-09-22 2025-06-26 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
MX2021014973A (es) * 2019-06-07 2022-04-18 Adimab Llc Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
AU2021236302A1 (en) 2020-03-12 2022-10-20 Immune-Onc Therapeutics, Inc. Novel anti-LILRB4 antibodies and derivative products
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
CA3217391A1 (en) * 2020-07-27 2022-02-03 Youwei ZHU Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
US11795224B2 (en) * 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
EP4314075A4 (en) * 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
CN118922442A (zh) * 2022-03-14 2024-11-08 成都盛世君联生物技术有限公司 一种抗cd3抗体及其制备方法和用途
CN115286715B (zh) * 2022-05-18 2023-05-23 上海百英生物科技股份有限公司 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法
JP2026502768A (ja) * 2022-10-25 2026-01-27 アブレクシス， エルエルシー 抗ｃｄ３抗体
JP2025540716A (ja) 2022-11-24 2025-12-16 ウーシー バイオロジクス アイルランド リミテッド Ｐｓｍａ抗体およびその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520600A (ja) 2013-05-28 2016-07-14 ヌマブ アクチェンゲゼルシャフト 新規抗体
JP2017504314A (ja) 2013-12-17 2017-02-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
JP2018513831A (ja) 2015-01-23 2018-05-31 サノフイ 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CN1169953C (zh) * 1999-11-30 2004-10-06 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd3单克隆抗体重链和轻链可变区基因及其应用
CN1984931B (zh) * 2004-06-03 2012-11-28 诺维莫尼公司 抗-cd3抗体及其使用方法
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2009010611A (es) * 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
US20110293619A1 (en) 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
WO2011109588A1 (en) * 2010-03-03 2011-09-09 Health Research Inc. Novel cd3 epsilon immunogens and antibodies
CN104098698B (zh) * 2013-04-08 2019-04-05 中国人民解放军第二军医大学 一种抗cd3抗体及其制法和应用
CN106459201A (zh) * 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520600A (ja) 2013-05-28 2016-07-14 ヌマブ アクチェンゲゼルシャフト 新規抗体
JP2017504314A (ja) 2013-12-17 2017-02-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
JP2018513831A (ja) 2015-01-23 2018-05-31 サノフイ 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体

Also Published As

Publication number Publication date
SG11202001358RA (en) 2020-03-30
KR20250046337A (ko) 2025-04-02
EP3684806A1 (en) 2020-07-29
US20230192850A1 (en) 2023-06-22
KR102785140B1 (ko) 2025-03-25
MY199530A (en) 2023-11-03
WO2019057099A1 (en) 2019-03-28
ZA202001314B (en) 2021-08-25
SA523440043B1 (ar) 2024-02-08
CN111108119B (zh) 2022-11-15
CA3074130A1 (en) 2019-03-28
JP2023126851A (ja) 2023-09-12
US11440962B2 (en) 2022-09-13
US20200299384A1 (en) 2020-09-24
TWI820041B (zh) 2023-11-01
AU2018336519A1 (en) 2020-03-05
JP2020534830A (ja) 2020-12-03
NZ762170A (en) 2023-10-27
IL273393B1 (en) 2026-02-01
MX2020003087A (es) 2020-08-17
EP3684806A4 (en) 2021-09-22
US12485298B2 (en) 2025-12-02
TW201922787A (zh) 2019-06-16
US20260116974A1 (en) 2026-04-30
IL325604A (en) 2026-02-01
IL273393A (en) 2020-05-31
CN111108119A (zh) 2020-05-05
TW202428617A (zh) 2024-07-16
BR112020004992A2 (pt) 2020-10-06
TWI879275B (zh) 2025-04-01
KR20200055052A (ko) 2020-05-20
EA202090800A1 (ru) 2020-08-11
CN115991777A (zh) 2023-04-21
AU2025201457A1 (en) 2025-03-20
SA520411577B1 (ar) 2024-02-08
AU2018336519B2 (en) 2024-12-19
PH12020550078A1 (en) 2022-07-18
JP7737193B2 (ja) 2025-09-10

Similar Documents

Publication Publication Date Title
JP7305624B2 (ja) 新規抗ＣＤ３ε抗体
WO2019179388A1 (en) Novel anti-ctla-4 antibody polypeptide
US20220089758A1 (en) Novel anti-cd40 antibodies
WO2019179434A1 (en) Novel bispecific pd-1/cd47 antibody molecules
JP7438180B2 (ja) 新規抗ｌａｇ－３抗体ポリペプチド
KR20230110546A (ko) 이작용성 분자
US20220348674A1 (en) Novel anti-cd40 antibodies
JP2024521045A (ja) 新規抗ｃｄ２７６抗体およびその使用
JP2025523359A (ja) 新規抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄおよびｃｄ３に結合する二特異性抗原結合分子、ならびにその使用
WO2020192709A1 (en) Novel bispecific polypeptide complexes
WO2019179421A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
US12486325B2 (en) Anti-CD3epsilon antibodies
US12202894B2 (en) Anti-TIM-3 antibodies
EA051013B1 (ru) Новые анти-cd3эпсилон антитела
EA042856B1 (ru) Новые анти-cd3-эпсилон антитела
TW202317618A (zh) 新型抗ｃｄ２７６抗體及其用途
NZ762170B2 (en) Novel anti-cd3epsilon antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230628

R150 Certificate of patent or registration of utility model

Ref document number: 7305624

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150